Zydus Lifesciences Limited — Updates, 05-02-2025: Press Release

Zydus Lifesciences Limited has reported impressive financial performance for Q3 FY25, with revenue from operations reaching ₹52,691 mn, representing a 17% year-on-year growth. The net profit surged by 30% to ₹10,235 mn, driven by higher demand and effective strategic execution. The EBITDA also saw a notable increase of 26% year-on-year, reaching ₹13,876 mn, with an improved margin of 26.3%.

The nine-month performance reflects a similar growth trajectory, with total revenue hitting ₹167,136 mn, up 19% year-on-year, and a net profit of ₹33,546 mn, marking a 25% increase. The company’s focus on Research & Development remains strong, with Q3 investments at ₹5,031 mn, accounting for 9.5% of revenue.

In terms of business segments, the US formulations business demonstrated remarkable growth, generating ₹24,096 mn, while the Indian market contributed ₹19,470 mn, aided by a 7% rise in revenue. Zydus is also expanding its portfolio, highlighted by the acquisition of Naturell (India) Pvt. Ltd, allowing entry into the consumer snacking market. The outlook remains positive with expectations for continued growth and strategic expansion initiatives across key sectors.